SOLICIP, SOLIFENACIN CIPLA, SOLIFENACIN CPL (Cipla Australia Pty Ltd)
Product name
SOLICIP, SOLIFENACIN CIPLA, SOLIFENACIN CPL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
133 working days (255)
Active ingredients
Solifenacin succinate
Registration type
New generic medicine
Indication
SOLICIP, SOLIFENACIN CIPLA, SOLIFENACIN CPL (tablets) is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.